Catalyst

Slingshot members are tracking this event:

AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ACRX Community voting in process

Additional Information

Additional Relevant Details "Evolution of Patient-Controlled Analgesia: From Intravenous to Sublingual Treatment" has been published in the peer-reviewed journal, Hospital Pharmacy. This article provides insights into patient-controlled analgesia (PCA) systems, the choice of opioid, risks, and costs associated with PCA usage in U.S. hospitals. Beyond intravenous (IV) PCA, the article also discusses noninvasive options in development, such as the transdermal, inhaled, oral and sublingual delivery of opioids.Zalviso (sufentanil sublingual tablet system) is profiled as a novel sublingual PCA system in development, and the entirety of the clinical program is reviewed.
http://ir.acelrx.com...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Opioid Patient-ctonrolled Analgesia, Pharmacoeconomics